BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 20, 2025
Home » Topics » Science » Artificial intelligence

Artificial intelligence
Artificial intelligence RSS Feed RSS

Software screenshot

FDA clears 510(k) for See-Mode Technologies’ AI software to better detect strokes

Oct. 20, 2020
By Tamra Sami
PERTH, Australia – See-Mode Technologies has received 510(k) clearance from the U.S. FDA to market its Augmented Vascular Analysis (AVA) program that uses artificial intelligence (AI) to analyze vascular ultrasound scans to better predict stroke. Caused by plaque that ruptures in blood vessels and blocks blood flow to the brain, stroke affects roughly 15 million people per year and is the second-leading cause of death globally.
Read More
Cambridge-1 supercomputer

Nvidia investing $52M in U.K. supercomputer for drug discovery

Oct. 5, 2020
By Nuala Moran
LONDON – U.S. chipmaker Nvidia Inc. is investing £40 million (US$51.9 million) in building a supercomputer in Cambridge, U.K., to be dedicated to applying artificial intelligence in drug discovery and in health care.
Read More
South Korean flag on building
2020 Bioplus Interphex Korea Conference

Vuno aims for Kosdaq listing by early 2021

Sep. 23, 2020
By Gina Lee
HONG KONG – Seoul, South Korea-based Vuno Inc. reported that it plans to list on South Korea’s Kosdaq bourse either by the end of 2020 or early next year, CTO and cofounder Kyu-hwan Jung told the 2020 Bioplus Interphex Korea Conference. After receiving A ratings in the recent technology evaluations by assessment institutions NICE D&B and Korea Enterprise Data, Vuno submitted a preliminary examination application to the bourse on July 28 that is currently underway, the company said.
Read More
2020 KoNECT-MOHW-MFDS International Conference

SK C&C looks to AI to enhance Korean drug discovery process

Sep. 15, 2020
By Gina Lee
HONG KONG – The Korean 2020 KoNECT-MOHW-MFDS International Conference, which is taking place online this year due to the COVID-19 pandemic, faced a challenging start. Technical difficulties hampered some of the early proceeding. However, technology took focus again later in the day in a more positive, with an exploration of artificial intelligence (AI).
Read More
2020 KoNECT-MOHW-MFDS International Conference

Implementing AI in the drug discovery process is difficult but not impossible

Sep. 15, 2020
By Gina Lee
HONG KONG – The use of artificial intelligence in drug discovery was back in the spotlight on the last day of the 2020 KoNECT-MOHW-MFDS International Conference, with drug developers pointing out both challenges and possible solutions.
Read More
2020 KoNECT-MOHW-MFDS International Conference

Implementing AI in the drug discovery process is difficult but not impossible

Sep. 11, 2020
By Gina Lee
HONG KONG – The use of artificial intelligence in drug discovery was back in the spotlight on the last day of the 2020 KoNECT-MOHW-MFDS International Conference, with drug developers pointing out both challenges and possible solutions.
Read More
Molecule illustration

Bayer leaps in to lead Recursion’s $239M series D

Sep. 9, 2020
By Lee Landenberger
Recursion Inc.’s combination of machine learning and artificial intelligence, coupled to its wet lab work, caught Bayer AG’s attention so solidly that its investment unit, Leaps by Bayer, led the charge on Recursion’s new and oversubscribed $239 million series D financing.
Read More
2020 KoNECT-MOHW-MFDS International Conference

SK C&C looks to AI to enhance Korean drug discovery process

Sep. 9, 2020
By Gina Lee
HONG KONG – The Korean 2020 KoNECT-MOHW-MFDS International Conference, which is taking place online this year due to the COVID-19 pandemic, faced a challenging start. Technical difficulties hampered some of the early proceeding. However, technology took focus again later in the day in a more positive, with an exploration of artificial intelligence (AI).
Read More
AI silhouette
Ai4 2020

High potential with AI/ML; pitfalls are incomplete data and people

Aug. 24, 2020
By Karen Carey
While the retail, security and entertainment sectors dove in early with the adoption of artificial intelligence (AI) and machine learning (ML) technologies, the life sciences sector has “been a bit of a laggard, frankly,” said Pratap Khedkar, a principal at the Evanston, Ill.-based consultant firm ZS Associates.
Read More
Hod Lipson, professor and robotics engineer, Columbia University
Ai4 2020

Artificial intelligence applications in health care on the rise

Aug. 20, 2020
By Karen Carey
Columbia University professor and robotics engineer Hod Lipson knows the importance of artificial intelligence (AI) on a global level. “It permeates everything we do, from the stock market, from predicting the weather to what product you’re going to buy,” he said Wednesday during the second day of the virtual Ai4 2020 conference. “It’s even grading essays. You name it.”
Read More
Previous 1 2 … 23 24 25 26 27 28 29 30 31 … 34 35 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing